Cargando…

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale

BACKGROUND: Statins are generally well-tolerated and serious side effects are infrequent, but some patients experience adverse events and reduce their statin dose or discontinue treatment altogether. Alirocumab is a highly specific, fully human monoclonal antibody to proprotein convertase subtilisin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teramoto, Tamio, Kondo, Akira, Kiyosue, Arihiro, Harada-Shiba, Mariko, Ishigaki, Yasushi, Tobita, Kimimasa, Kawabata, Yumiko, Ozaki, Asuka, Baccara-Dinet, Marie T., Sata, Masataka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474052/ https://www.ncbi.nlm.nih.gov/pubmed/28623954 http://dx.doi.org/10.1186/s12944-017-0513-7

Ejemplares similares

Efficacy and Safety of Alirocumab in Japanese Patients with Diabetes Mellitus: Post-hoc Subanalysis of ODYSSEY Japan
por: Teramoto, Tamio, et al.
Publicado: (2019)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
por: Kastelein, John J. P., et al.
Publicado: (2014)

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
por: Nam, Chang-Wook, et al.
Publicado: (2019)

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
por: Stroes, Erik, et al.
Publicado: (2016)

Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials
por: Leiter, L. A., et al.
Publicado: (2017)

Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials
por: Bays, Harold E., et al.
Publicado: (2018)

Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials
por: Catapano, Alberico L., et al.
Publicado: (2017)

Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
por: Jukema, J. Wouter, et al.
Publicado: (2019)

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
por: Colhoun, Helen M., et al.
Publicado: (2016)

Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE
por: Banach, Maciej, et al.
Publicado: (2021)

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
por: Kastelein, John J.P., et al.
Publicado: (2015)

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy
por: Kajinami, Kouji, et al.
Publicado: (2019)

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
por: Cannon, Christopher P., et al.
Publicado: (2015)

Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial
por: Ray, Kausik K., et al.
Publicado: (2018)

Moving Branded Statins to Lowest Copay Tier Improves Patient Adherence
por: Chen, Shih-Yin, et al.
Publicado: (2014)

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
por: Kühnast, Susan, et al.
Publicado: (2014)

Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
por: Szarek, Michael, et al.
Publicado: (2020)

Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
por: Schwartz, Gregory G, et al.
Publicado: (2023)

Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial
por: Murphy, William A., et al.
Publicado: (2022)

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
por: Langslet, Gisle, et al.
Publicado: (2020)

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
por: White, Harvey D, et al.
Publicado: (2019)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
por: Ginsberg, Henry N., et al.
Publicado: (2016)

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial
por: Moriarty, Patrick M., et al.
Publicado: (2016)

Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials
por: Leiter, L. A., et al.
Publicado: (2018)

Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study
por: Bruckert, Eric, et al.
Publicado: (2022)

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
por: Colhoun, Helen M, et al.
Publicado: (2014)

Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
por: Steg, Philippe Gabriel, et al.
Publicado: (2019)

Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin
por: Müller-Wieland, Dirk, et al.
Publicado: (2019)

Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies
por: Ginsberg, Henry N., et al.
Publicado: (2018)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study
por: Li, Haiyan, et al.
Publicado: (2020)

Effects of Statins on Cardiorenal Syndrome
por: Yagi, Shusuke, et al.
Publicado: (2012)

Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials
por: Ganda, Om P., et al.
Publicado: (2018)

Lipid‐lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub‐analysis of ODYSSEY COMBO II
por: Leiter, Lawrence A., et al.
Publicado: (2017)

Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab
por: Vallejo-Vaz, Antonio J, et al.
Publicado: (2020)

Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis
por: Sinnaeve, Peter R, et al.
Publicado: (2020)

The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability
por: Rosenson, Robert S, et al.
Publicado: (2017)

Efficacy and Safety of Alirocumab as Add‐on Therapy in High–Cardiovascular‐Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies
por: Robinson, Jennifer G., et al.
Publicado: (2014)

Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control
por: Ray, Kausik K., et al.
Publicado: (2016)

Statin Intolerance and Suboptimal Statin Therapy
por: Tada, Hayato, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rukd9brbueig5lgnvmq48srsra